Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4079 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Par to distribute Spectrum’s generic drugs

The agreement covers three abbreviated new drug applications (ANDAs) Spectrum has already had approved by the FDA, and a further nine currently under review. The contract also covers

First generic of Glaxo’s Flonase is approved

The patent on Glaxo’s Flonase expired in November 2005, allowing Roxane, a subsidiary of Boehringer Ingelheim, to apply for approval of its generic product containing the same active

AstraZeneca partners Biosystems International

As a part of this program, BioSystems International will conduct biomarker discovery using its proprietary technology platform, whilst AstraZeneca will provide clinical samples and funding. BioSystems will retain

Mylan gets nod for Coreg generic

The FDA’s decision means that Mylan’s application is in order and the product will be approved pending patent expiry or legal issues surrounding the original drug. The drugs

Kos improves existing cholesterol drug

The company designed two separate studies, the first of which was a single dose, three-way crossover study of 156 participants evaluating a modified formulation (MF) of Niaspan designed

Jazz receives positive results for pain drug

Fibromyalgia syndrome is a chronic pain illness which is characterized by widespread musculoskeletal aches, pains and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common